People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NextPoint Therapeutics, Inc. | — | Biotechnology | Series C | $122.5M | $444.1M | 2022 |
| Faraday Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $115.5M | $830.5M | 2014 |
| Normunity Holding Company, LLC | — | Biotechnology | Series C | $83.4M | $273.5M | 2025 |
| Avilar Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $2.3B | 2020 |
| JW Celtics Investment Corp. | — | Biotechnology | Series A | $11.0M | $100.2M | 2023 |
Paulina Hill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paulina Hill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Robert Nelsen | 1 | 22 |
| Bryan Roberts | 1 | 18 |
| Joshua Resnick | 1 | 12 |
| Terrance McGuire | 1 | 9 |
| Timothy Shannon | 1 | 9 |
| Ansbert Gadicke | 1 | 7 |
| David Neafus | 1 | 7 |
| R. Jacob Vogelstein | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| Thomas King | 1 | 6 |
| Scott Phillips | 1 | 5 |
| Milind Deshpande | 1 | 4 |
| Sara Nayeem | 1 | 4 |
| Detlev Biniszkiewicz | 1 | 4 |
| Stephen Hill | 1 | 3 |
| Mark Roth | 1 | 3 |
| Darlene Deptula-Hicks | 1 | 3 |
| David Parry | 1 | 3 |
| Matthew Roden | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.